ALK and anaplastic large cell lymphoma: A large cohort study performed by the Center for International Blood and Marrow Transplant Research (CIBMTR) found that patients with relapsed ALCL undergoing auto-HCT had superior outcomes to those receiving allo-HCT with a smaller nonrelapse mortality at 100 days, 1 year, and 3 years, and superior PFS and OS at 1 and 3 years for the auto-HCT patients compared to allo-HCT patients, although this study also did not separate ALCL based on ALK status and patients had varying baseline characteristics36.